Results 1 to 10 of about 19,610 (201)
Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. [PDF]
Journal of Clinical Investigation, 1980 Prolongation of all phospholipid-dependent coagulation tests was found in a patient with macroglobulinemia, despite absence of bleeding manifestations. The purified monoclonal IgM lambda protein and its Fabmu tryptic fragment induced similar changes in normal plasma.
P, Thiagarajan +2 more
openaire +3 more sources
Lupus Anticoagulants and Their Relationship with the Inhibitors against Coagulation Factor VIII: Considerations on the Differentiation between the 2 Circulating Anticoagulants [PDF]
Clinical Chemistry, 2005 Lupus anticoagulants (LAs) are a heterogeneous group of immunoglobulins directed against negatively charged phospholipids in complex with proteins [β2-glycoprotein I (β2GPI), prothrombin and others] (1). LAs prolong phospholipid-dependent coagulation tests and are associated with increased risk of thrombosis and fetal loss (1). There are other types of
A. Tripodi +7 more
openaire +5 more sources
Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays [PDF]
Scandinavian Journal of Clinical and Laboratory Investigation, 2018 Edoxaban is an oral direct factor Xa inhibitor for prophylaxis and treatment of thromboembolic disorders. The effects on common coagulation assays are clinically valuable information and in certain clinical situations a quick assessment of the anticoagulant is wanted.
Andreas Hillarp +5 more
openaire +3 more sources
International Journal of Hematology and Oncology, 2012 Acquired coagulation inhibitors are rare but acquired bleeding diathesis caused by autoimmune depletion or dysfunction of coagulation factors can be life-threatening. This occurs most frequently in elderly patients who lack disease associations. Acquired coagulation inhibitors may also arise in association with systemic lupus erythematosus (SLE).
Özgür Erdem
openaire +2 more sources
Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors [PDF]
Thrombosis and Haemostasis, 2010 Non-parallelism in the one-stage coagulation factor assay is a phenomenon of lupus anticoagulants and not of individual factor inhibitors -
Ruinemans-Koerts, J. +2 more
openaire +4 more sources
Journal of Medical Case Reports, 2022 Background Acquired hemophilia A is a disorder caused by autoantibodies against coagulation factor VIII that may present with severe bleeding. We report a rare case of acquired hemophilia A presenting with coexisting lupus anticoagulant.
Victor Chen +4 more
doaj +1 more source
Lupus anticoagulant: a clinical and laboratory diagnostic dilemma
Journal of Pathology of Nepal, 2022 Lupus anticoagulants are a group of diverse autoantibodies that interfere in vitro in phospholipid-dependent clotting tests, and inhibit both the common and intrinsic pathways of coagulation. Paradoxically, they are implicated to cause hypercoagulability,
Shalini Trivedi +4 more
doaj +1 more source
Frontiers in Psychiatry, 2023 A patient with schizophrenia who was treated with chlorpromazine developed lupus anticoagulant (LA) and antiphospholipid syndrome (APS). On protein electrophoresis, a monoclonal immunoglobulin A peak was seen in this patient, defining a condition of ...
Yingming Jin +3 more
doaj +1 more source
TH Open, 2020 Lupus anticoagulant is a misnomer as it is commonly associated with thromboembolic events. In few cases, the name retains its literal meaning when it characterizes patients with a bleeding disorder.
Vittorio Pengo +7 more
doaj +1 more source